EP Patent

EP2785706A1 — Substituted 4 - phenyl - pyridines for the treatment of nk-1 receptor related diseases

Assigned to Helsinn Healthcare SA · Expires 2014-10-08 · 12y expired

What this patent protects

Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NKj) receptor. The compounds have the general formula (I):

USPTO Abstract

Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NKj) receptor. The compounds have the general formula (I):

Drugs covered by this patent

Patent Metadata

Patent number
EP2785706A1
Jurisdiction
EP
Classification
Expires
2014-10-08
Drug substance claim
No
Drug product claim
No
Assignee
Helsinn Healthcare SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.